H-Leu-Leu-OMe

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: H-Leu-Leu-OMe
• 英文别名: Methyl 2-[(2-amino-4-methylpentanoyl)amino]-4-methylpentanoate
• 化学式: C₁₃H₂₆N₂O₃
• mdl: MFCD12126030
• 分子量: 258.361
• InChiKey: AJMOLNFDYWTVQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.846
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  H-Leu-Leu-OMe 、 4-[(5-diazonio-2-nitrophenyl)carbonyl]-piperazin-1-yl-methyl-poly(styrene-co-divinylbenzene) tetrafluoroborate 生成 4-[(5-(1-(1-((methoxycarbonyl)(i-butyl)methylaminocarbonyl)-2-(i-propyl)ethyl)triaz-1-en-3-yl)-2-nitrophenyl)carbonyl]-piperazin-1-yl-methyl-poly(styrene-co-divinylbenzene)
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Improved process for preparing lymphokine activated killer cells
  申请人：TERUMO KABUSHIKI KAISHA

  公开号：EP0247613A2

  公开（公告）日：1987-12-02

  There are disclosed an improved process for preparing lymphokine activated killer (LAK) cells from peripheral blood mononuclear cells, a composition consisting essentially of the LAK cells prepared from the disclosed process in a pharmaceutically acceptable carrier, and a method of treating cancer comprising administering the disclosed composition to a patient suffering from said cancer.

  本发明公开了一种从外周血单核细胞制备淋巴因子活化杀伤细胞（LAK）的改进工艺，一种主要由在药学上可接受的载体中用公开工艺制备的 LAK 细胞组成的组合物，以及一种治疗癌症的方法，该方法包括将公开组合物施用给患有所述癌症的患者。
• Method for generating monoclonal antibodies from rabbits
  申请人：ELI LILLY AND COMPANY

  公开号：EP0583980A1

  公开（公告）日：1994-02-23

  This invention relates to a method for producing rabbit monoclonal antibodies employing a stable xenogeneic fusion partner. The stable xenogeneic fusion partner is a product of the fusion of a rodent myeloma cell and a non-transformed rabbit partner cell. A method for generating rabbit monoclonal antibodies is disclosed that comprises fusing a nontransformed rabbit partner cell with a rodent myeloma cell to produce a xenogeneic fusion partner, selecting a stable fusion partner producing undetectable levels of antibodies, fusing the stable fusion partner with a rabbit antibody producing cell and isolating an antibody producing cell line that produces antibodies directed to a predetermined antigen.

  本发明涉及一种利用稳定的异种融合伴侣生产兔单克隆抗体的方法。稳定的异种融合伙伴是啮齿类骨髓瘤细胞与非转化兔伙伴细胞融合的产物。本发明公开了一种产生兔单克隆抗体的方法，该方法包括将非转化兔伴侣细胞与啮齿类骨髓瘤细胞融合以产生异种融合伴侣，选择能产生检测不到的抗体水平的稳定融合伴侣，将稳定融合伴侣与兔抗体产生细胞融合，并分离出能产生针对预定抗原的抗体的抗体产生细胞系。
• Preparation of fully human antibodies
  申请人：CCL Holdings Co., Ltd.

  公开号：EP1498426A1

  公开（公告）日：2005-01-19

  The present invention provides a method of preparing fully human antibodies that recognize a pre-determined antigen without relying on human donors that have already been exposed to the antigen. To this end, lymphocytes from naive human donors are immunized in vitro with the antigen of interest, and cells that produce antibodies against the antigen are identified. Since the lymphocytes are immunized in vitro rather than in vivo, it is possible to control which antigen, or which part of the antigen, would be recognized by the antibody. A preferred antigen is gp120 of HIV, particularly the co-receptor binding region of gp120.

  本发明提供了一种制备可识别预定抗原的全人抗体的方法，无需依赖已接触过抗原的人体供体。为此，用相关抗原体外免疫天真人类供体的淋巴细胞，并鉴定产生抗原抗体的细胞。由于淋巴细胞是在体外而不是体内免疫的，因此可以控制抗体识别哪种抗原或抗原的哪一部分。首选的抗原是艾滋病毒的 gp120，特别是 gp120 的共受体结合区。
• TUMORICIDAL T LYMPHOCYTES
  申请人：——

  公开号：US20020039569A1

  公开（公告）日：2002-04-04

  The present invention concerns a mammalian cell line which when co-cultured with lymphocytes during which allogenic stimulation is avoided activates lymphocytes fo form tumoricidal cells, a process for the production of tumoricidal T lymphocytes by co-culturing lymphocytes with this cell line, the tumoricidal T lymphocytes obtained by means of this process and the use of the cells according to the present invention for the production of a therapeutic agent which can be used in tumour therapy.

  本发明涉及一种哺乳动物细胞系，该细胞系在与淋巴细胞共同培养过程中避免了异源刺激，可激活淋巴细胞形成肿瘤杀伤细胞；还涉及一种通过与该细胞系共同培养淋巴细胞生产肿瘤杀伤T淋巴细胞的工艺、通过该工艺获得的肿瘤杀伤T淋巴细胞，以及根据本发明使用该细胞生产可用于肿瘤治疗的治疗剂。
• 4H-3,1-benzoxazin-4-ones and related compounds, pharmaceutical compositions containing them, and processes for their preparation
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0147211B1

  公开（公告）日：1990-09-12